A study investigating the effects of sitagliptin on heart muscle performance in patients with heart disease and diabetes

The effects of sitagliptin (Januvia®) on myocardial performance in patients with coronary artery disease

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN78649100

Enrollment

Registered

2008-07-11

Start date

2008-08-01

Completion date

Unknown

Last updated

2015-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Coronary artery disease Circulatory System Chronic ischaemic heart disease

Interventions

Subjects undergo two dobutamine stress echoes (DSE) (which last about half an hour) one week apart. Before the control DSE they are given a 75 g solution of glucose to drink. Before the other DSE they

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Subjects aged 35 - 80 years with coronary disease awaiting revascularisation with normal left ventricular (LV) function with insulin resistance.

Exclusion criteria

Exclusion criteria: 1. Atrial fibrillation 2. Pacemakers 3. Valvular heart disease 4. Renal failure

Design outcomes

Primary

Measure	Time frame
LV performance during dobutamine stress echocardiography (wall motion scoring and ejection fraction [EF]), taken at baseline, peak dobutamine stress and in recovery for each DSE.	—

Secondary

Measure	Time frame
1. Tissue Doppler 2. Strain imaging 3. Strain rate These outcome measures are taken at baseline, peak dobutamine stress and in recovery for each DSE.	—

Countries

United Kingdom

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Apr 1, 2026